Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
11.12
-0.54 (-4.63%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Surrozen Revenue
In the year 2024, Surrozen had annual revenue of $10.66M. Surrozen had revenue of $655.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$10.66M
Revenue Growth
n/a
P/S Ratio
3.21
Revenue / Employee
$253,690
Employees
42
Market Cap
94.11M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SRZN News
- 1 day ago - Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 8 days ago - Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases - GlobeNewsWire
- 5 months ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 5 months ago - Surrozen Provides Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 5 months ago - Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 6 months ago - Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - GlobeNewsWire
- 8 months ago - Surrozen Provides Second Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 10 months ago - Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling - GlobeNewsWire